Swanbridge invests in Pan Cancer T

Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center – Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and Van Herk Ventures with support from...

Swanbridge Capital invests in Immagene

Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics   Immagene B.V. launched this month as a private biotech company developing next-generation precision immuno-oncology (IO) treatments. The company based in...